Education
About Us
Working with TipRanks
Follow Us
Agenus (AGEN)
NASDAQ:AGEN
AGEN Stock Chart & Stats
$2.89
-$0.06(-1.69%)
At close: 4:00 PM EST
$2.89
-$0.06(-1.69%)
Day’s Range― - ―
52-Week Range$1.38 - $7.34
Previous CloseN/A
Volume199.21K
Average Volume (3M)754.30K
Market Cap
$98.28M
Enterprise Value$140.60M
Total Cash (Recent Filing)$3.46M
Total Debt (Recent Filing)$45.77M
Price to Earnings (P/E)―
Beta3.43
Next Earnings
Mar 12, 2026EPS Estimate
-1.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.94
Shares Outstanding34,008,350
10 Day Avg. Volume658,527
30 Day Avg. Volume754,301
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-0.18
Price to Sales (P/S)0.57
P/FCF Ratio-0.37
Enterprise Value/Market Cap1.43
Enterprise Value/Revenue1.32
Enterprise Value/Gross Profit1.63K
Enterprise Value/Ebitda4.22
Forecast
1Y Price Target
$23.00Price Target Upside695.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Data And Regulatory AccessPositive Phase 1b pan-tumor data showing durable responses and a 39% two-year overall survival in late-line patients, together with compassionate-use authorization in France, strengthens clinical credibility and signals encouraging regulatory interest for pivotal studies.
Manufacturing Capacity And CapitalSale of California manufacturing facilities to the partner establishes a contract manufacturing relationship that secures prioritized production capacity and injects capital to support late-stage development and regulatory preparation.
Strategic Collaboration And CommercializationStrategic collaboration with a large pharmaceutical partner provides an equity investment and exclusive rights to develop and commercialize the therapies in India and Sri Lanka, creating a defined commercial pathway in a large, growing market.
Bears Say
Agenus News
AGEN FAQ
What was Agenus’s price range in the past 12 months?
Agenus lowest stock price was $1.38 and its highest was $7.34 in the past 12 months.
What is Agenus’s market cap?
Agenus’s market cap is $98.28M.
When is Agenus’s upcoming earnings report date?
Agenus’s upcoming earnings report date is Mar 12, 2026 which is in 34 days.
How were Agenus’s earnings last quarter?
Agenus released its earnings results on Nov 10, 2025. The company reported $1.94 earnings per share for the quarter, missing the consensus estimate of $2.197 by -$0.257.
Is Agenus overvalued?
According to Wall Street analysts Agenus’s price is currently Undervalued.
Does Agenus pay dividends?
Agenus does not currently pay dividends.
What is Agenus’s EPS estimate?
Agenus’s EPS estimate is -1.04.
How many shares outstanding does Agenus have?
Agenus has 34,008,350 shares outstanding.
What happened to Agenus’s price movement after its last earnings report?
Agenus reported an EPS of $1.94 in its last earnings report, missing expectations of $2.197. Following the earnings report the stock price went up 5.779%.
Which hedge fund is a major shareholder of Agenus?
Currently, no hedge funds are holding shares in AGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agenus Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$23.00 (695.85% Upside)
$23.00 (695.85% Upside)
Blogger Sentiment
Neutral
AGEN Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 54.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.37%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.93%
Trailing 12-Months
Company Description
Agenus
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
AGEN Stock 12 Month Forecast
Average Price Target
$23.00
▲(695.85% Upside)
Technical Analysis
Inovio Pharmaceuticals
―
Oncolytics Biotech
―
―
TuHURA Biosciences
―
Spero Therapeutics
―
Instil Bio
―
Ownership Overview
2.19% Insiders
11.27% Mutual Funds
0.04% Other Institutional Investors
82.31% Public Companies and
Individual Investors